Quidel Q4 Revenues Shrink 7 Percent on Softer Flu Business; MDx Projects Remain on Track | GenomeWeb

NEW YORK (GenomeWeb News) – Quidel reported after the close of the market on Tuesday that its fourth quarter revenues declined 7 percent year over year on slower influenza and respiratory disease business.

The San Diego-based diagnostics company saw its revenues during the three months ended Dec. 31, 2013 retreat to $50.2 million from $53.9 million in the year-ago period, but still beat the consensus analyst estimate of $48.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.